Answers are grounded in this paper and cite their sources.
While infliximab at 3 mg/kg and 6 mg/kg showed durable efficacy at 1 year, achievement of the primary efficacy end point at 3 months did not differ significantly between infliximab-treated and placebo-treated patients. Safety data indicated that the 6-mg/kg dose may provide a more favorable risk/benefit profile. These results warrant further investigation in children with JRA.
No takes yet. Share an insight, caveat, or question.
Ruperto et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: